An interventional study of Whole-exome sequencing in Cerebral Palsy, sponsored by Hospices Civils de Lyon. Recruiting at 2 sites in France. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2025-03-03.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Screening
Among 12 studies in Cerebral Palsy by Hospices Civils de Lyon — 4 open to participants now, 4 under way, none of them phase 3. Cerebral Palsy · Hospices Civils de Lyon.
Among the 12 studies in Cerebral Palsy by Hospices Civils de Lyon, this one is the only one that started in 2023, is one of 5 with no phase, and was the 9th registered.
1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.
This study's planned enrollment of 250 is above the median of 34 across 1,431 interventional studies indexed under Cerebral Palsy.
Browse Cerebral Palsy studies →4 of the 12 studies in Cerebral Palsy by Hospices Civils de Lyon are open now, in 1 country. Each count lists the studies.
Of the 270 Cerebral Palsy studies recruiting now, 27 (10%) set no upper age limit and 235 (87%) stop at 75 or younger; 255 take children under 18; 51 take healthy volunteers.
This study: 2 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
Median enrollment 23 across the 7 interventional studies, 150 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
1 of the studies in Cerebral Palsy by Hospices Civils de Lyon that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07915466Hospices Civils de LyonPeripheral Neurotomies of the Upper Limb in Children With Cerebral Palsy. | 2027-01-15 |
Among the 12 studies in Cerebral Palsy by Hospices Civils de Lyon, from their registry updates:
Cerebral palsy (CP) is a major neurodevelopmental disorder with an estimated prevalence of approximately one in 500 children. It is characterised by permanent developmental disorders of movement and posture, responsible for activity limitations, caused by non-progressive damage to the brain of the fetus, newborn or infant during development. The neurobiological mechanisms involved in CP remain poorly understood, although the interruption of cerebral oxygen supply during pregnancy or at the time of delivery is classically considered to be the main factor causing neurodevelopmental sequelae. CP also occurs in full-term infants without a clearly identifiable etiology.
Data from the literature suggest the existence of other pathophysiological processes than only acquired brain lesions related to pregnancy and delivery, such as genetic or epigenetic factors. According to some research teams, nearly one third of CP could have a genetic cause or could be favoured by genetic variants.
Preliminary research has made significant progress in revealing unusual copy number variants and/or mutations in single genes in children with CP. Several of the identified genes are involved in neurodevelopment and neuronal connectivity. Nevertheless, the identification of these abnormalities in CP may contribute to a better understanding of the pathophysiology of this complex and multifactorial disorder. It could also shed new light on the analysis of medico-legal files and bring encouraging perspectives by targeting new therapeutic interventions.
The main hypothesis is that a certain number of cerebral palsies are related to - or favoured by - genetic abnormalities that we will search for with genetic screening tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients between 2 and 15 years old, born after 34 weeks' gestation, with a diagnosis of cerebral palsy.
Genetic: Whole-exome sequencing
The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
Proportion of patients for whom a significant genetic variant was identified on the exome by the High-throughput sequencing technique after comparison with the databases of human polymorphisms and pathogenic variants up to date during the analysis.
Are considered positive for a significant genetic variant, patients for whom a or several class 4 or 5 variants have been identified, and explain the phenotype of pc. Genetic variants will be classified according to the recommendations of the American College of Genetics Medical (ACMG: American College of Medical Genetics) from 1 to 5.
Time frame: Until the end of study, an average of 4.5 years
Started Sep 2023 (actual). Primary completion is estimated for Mar 2028, 54 months after the start.
Of 902 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 54 months is above that.
Counting every sponsor, half of 921 studies reached it within 12 months; a quarter within 5 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.